Our team of digital CMC experts is thrilled to be joining forces with one of the life sciences’ leading transformation consultancies. Find out how we aim to help customers achieve new levels of efficiency, integration, and productivity.
Today’s drug developers are deluged with unstructured data. In this first post of a new series, find out how pharma and biotech companies are struggling to manage their information resources.
Software like QbDVision and guidance from ISPE and Validation 4.0 are revolutionizing drug development with digital tools and better process. Read more about these changes.
Worried about data breaches that could expose your CMC data? You should be. Find out how a few essential steps can help you level up the safeguards on your invaluable IP.
Two decades ago, the ICH’s M4Q guideline provided an invaluable bridge between CTD Modules 2 and 3. Now, a timeline revision promises to accelerate the industry’s shift to digital CMC.
New drug products are calling for more innovative raw materials than ever. See why registering them with QbD principles is the new way forward for CMC programs.
Miss the live event? Stream all 8 sessions from this year’s summit on-demand, including in-depth presentations, panel discussions, Q&A, and more.
CMC programs produce a wealth of insight-rich data. Here’s how the right data framework could help unlock its value.
Compliance Architects® Identifies QbDVision as Best-In-Class Platform to Drive Structural Compliance in Drug Development
We are thrilled to announce that we are partnering with Compliance Architects (CA) to combine the power of our QbDVision Digital CMC™ software platform with CA’s deep experience in quality and regulatory compliance. Together, we plan to accelerate the development of robust manufacturing processes for pharma and biotech products.